CClinicalTrials.gg
Not yet recruitingNCT01687127Updated Aug 15, 2023

Impact of High-dose Folic Acid Supplementation on Pathways Linked to DNA Formation

An interventional study of Folic acid and 5-methyltetrahydrofolate, calcium salt in One-carbon Metabolism in Healthy Individuals, sponsored by University of British Columbia. Not yet recruiting at 1 site in Canada. Open to female participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-15.

Sponsored by University of British Columbia · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Female
01

Study summary

Periconceptional supplementation with folic acid - the synthetic form of the B-vitamin folate - reduces the occurrence of adverse pregnancy outcomes such as spina bifida. The underlying biochemical mechanisms for how folic acid affects health outcomes however are unknown. The naturally occurring form 5-methyltetrahydrofolate (5-MTHF) is now available and discussed as an adequate substitute to folic acid. This study aims to determine the effect of folic acid compared to 5-MTHF on cellular mechanisms. Stable isotope tracer protocols will be used that allow determining the effect of folic acid on the dynamics of metabolic pathways in the human body.

Hypothesis: Supplementation with high-dose folic acid alters the turnover rate of folate dependent pathways in healthy humans; but 5-MTHF does not. Genetic variations in a key enzyme of the folate metabolism will aggravate the effect of folic acid on the metabolic pathways.

02

Conditions studied

  • One-carbon Metabolism in Healthy Individuals

Keywords

  • folic acid
  • folate
  • 5-methyltetrahydrofolate
  • supplements
  • women
  • one-carbon metabolism
  • methionine
  • DNA methylation
  • in vivo kinetics
03

In context

Lead sponsor

University of British Columbia is the lead sponsor of 1,309 studies on the registry; 253 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Generally healthy
  • Body mass index of between 19-24 kg/m2
  • Normal folate, vitamin B12, and B6 status

Exclusion criteria

Exclusion Criteria:

  • Unable to swallow tablets
  • Unable to receive intravenous catheters
  • Use of vitamin supplements, amino acid or protein supplements for more than six months before study participation
  • Chronic consumption of a high-protein diet (e.g. Atkins Diet)
  • Medical conditions such as diabetes, asthma, cancer, cardiovascular disease, a history of neural tube defect (such as spina bifida) affected pregnancy, have had gastrointestinal surgery, abnormal kidney, thyroid function, or psychiatric illness, or any other chronic disease
  • Pregnancy or lactation
  • Smoking, use of recreational drugs, and/or consumption of more than one alcohol drink per day or more than seven per week.
  • Use of long-term prescription medication such as hormonal contraceptives, antidepressants, anticonvulsants, anticoagulants, or other chronic medication
  • Blood donation in the last three months prior to study start
  • Unable to provide informed consent, or unable to read and write English
  • Low compliance to intervention as determined by early steady-state or reduction in blood folate concentrations
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Folic acid supplementation

    Folic acid will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism.

    Dietary Supplement: Folic acid

  • Experimental
    5-MTHF supplementation

    The calcium salt of 5-methyltetrahydrofolate (5-MTHF; Brand name "Metafolin") will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism.

    Dietary Supplement: 5-methyltetrahydrofolate, calcium salt

Interventions

  • Dietary supplementFolic acid

    Supplement

    Also known as: Pteroylmonoglutamic acid

  • Dietary supplement5-methyltetrahydrofolate, calcium salt

    Supplement

    Also known as: 5-MTHF, Metafolin (brand name), Levomefolic acid

06

What researchers measure

Primary outcomes

  1. Plateau enrichment of infused amino acid tracers and related metabolites to quantify turnover rates of folate dependent pathways

    Time frame: 24 weeks

07

Study locations

1 site
  • Children's and Women's Health Centre of BC (incl. Sunny Hill), Child and Family Research Institute
    Vancouver, British Columbia V5Z 4H4, Canada
    • Yvonne Lamers, PhD · Contact · yvonne.lamers@ubc.ca · 604-827-1776
    • Amy McMahon, PhD · Contact · amy.mcmahon@ubc.ca · 604-822-1250
    • Jehannine C Austin, PhD · Sub investigator
    • Amanda Skoll, MD, FRCSC · Sub investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01687127
Lead sponsor
University of British Columbia
Responsible party
Yvonne Lamers (Principal Investigator, University of British Columbia) — Principal investigator
First posted
Sep 18, 2012
Start date
Jan 1, 2024 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 15, 2023

Study contacts

Yvonne Lamers, PhD
Contact
yvonne.lamers@ubc.ca
604-827-1776
Amy McMahon, PhD
Contact
amy.mcmahon@ubc.ca
604-822-1250
Yvonne Lamers, PhD
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion